Enpatoran in COVID‐19 pneumonia: Safety and efficacy results from a phase II randomized trial

• Main Authors: John E. McKinnon (Author), Joel Santiaguel (Author), Claudia Murta de Oliveira (Author), Dongzi Yu (Author), Mukhy Khursheed (Author), Flavie Moreau (Author), Lena Klopp‐Schulze (Author), Jamie Shaw (Author), Sanjeev Roy (Author), Amy H. Kao (Author), the ANEMONE Study Team (Author)
• Format: Book
• Published: Wiley, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Enpatoran is a selective inhibitor of toll‐like receptors 7 and 8 (TLR7/8) that potentially targets pro‐inflammatory pathways induced by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A phase II study conducted in Brazil, the Philippines, and the USA during the early pandemic...